Start with the basics: get a handle on what AI is, why it matters, and how it’s used in the real world. Make a plan: figure ...

Algebra Ace releases '9th Grade Algebra Made Easy,' an affordable interactive guide using Desmos technology to help visual ...

A study of data from 2,000 students highlights the best strategies for catching kids up and ensuring they pass this key subject.

PD-1/IL-2 α-bias bispecific antibody fusion protein IBI363 in patients with immunotherapy resistant advanced non-small cell lung cancer: results from a Phase 1 study Updated data on IBI363 monotherapy ...

Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data Jun. 02, 2025 2:55 PM ET Kymera Therapeutics, Inc. (KYMR) Stock SNY , REGN , SNYNF , KYMR 1 Comment Terry Chrisomalis ...

U.S. Phase 1/2a Study of VS-7375 The Phase 1/2a study will be conducted in the U.S., with the potential to expand globally, and will evaluate the safety and efficacy of VS-7375 in patients with ...

CAMBRIDGE, MA, USA I May 23, 2025 I Nona Biosciences, a global biotechnology company providing integrated solutions from “Idea to IND” (I to I TM), today announced that its collaborator, Pfizer, will ...

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the iMMagine-1 Trial Speaker : ...

A study co-led by Indiana University School of Medicine researchers presents a potential new strategy to prevent or slow the progression of Type 1 diabetes by targeting an inflammation-related ...

MINNEAPOLIS, May 03, 2025 (GLOBE NEWSWIRE) -- Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes (T2D), presented significant ...

TGW101 is being evaluated in an ongoing, open-label, multicenter, phase 1 dose-escalation study for the treatment of patients with advanced solid tumors. The primary end points of the trial are to ...

(RTTNews) - Protara Therapeutics, Inc. (TARA), Wednesday announced that data from its THRIVE-1 study will be presented at the American Society for Parenteral and Enteral Nutrition or ASPEN 2025 ...